...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature Communications >Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
【24h】

Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma

机译：系统地优化的BCMA / CS1双特异性CAR-T细胞鲁棒地控制异质多发性骨髓瘤

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Chimeric antigen receptor (CAR)-T cell therapy has shown remarkable clinical efficacy against B-cell malignancies, yet marked vulnerability to antigen escape and tumor relapse exists. Here we report the rational design and optimization of bispecific CAR-T cells with robust activity against heterogeneous multiple myeloma (MM) that is resistant to conventional CAR-T cell therapy targeting B-cell maturation antigen (BCMA). We demonstrate that BCMA/CS1 bispecific CAR-T cells exhibit superior CAR expression and function compared to T cells that co-express individual BCMA and CS1 CARs. Combination therapy with anti-PD-1 antibody further accelerates the rate of initial tumor clearance in vivo, while CAR-T cell treatment alone achieves durable tumor-free survival even upon tumor re-challenge. Taken together, the BCMA/CS1 bispecific CAR presents a promising treatment approach to prevent antigen escape in CAR-T cell therapy against MM, and the vertically integrated optimization process can be used to develop robust cell-based therapy against novel disease targets.
机译：嵌合抗原受体（汽车）-T细胞疗法对B细胞恶性肿瘤的临床疗效表现出显着的临床疗效，但对抗原逃逸和肿瘤复发的脆弱性显着脆弱。在这里，我们报告了具有稳健活性的双特异性的Car-T细胞的合理设计和优化，其对靶向B细胞成熟抗原（BCMA）的常规Car-T细胞疗法抵抗常规的多骨瘤（MM）。我们证明BCMA / CS1双特异性CAR-T细胞与共同表达单独的BCMA和CS1汽车的T细胞相比表现出优异的汽车表达和功能。抗PD-1抗体的组合治疗进一步加速了体内初始肿瘤间隙的速率，而仅仅仍然可以在肿瘤重新攻击时实现耐用的无肿瘤生存率。在一起，BCMA / CS1双特异性轿厢呈现了有希望的处理方法，以防止抗原逸出对毫米的Car-T细胞疗法，并且垂直整合的优化过程可用于开发对新型疾病目标的鲁棒细胞疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号